Login to Your Account

CardioKine Brings In $50M Via Series B For Lixivaptan

By Karen Pihl-Carey

Tuesday, May 2, 2006
CardioKine Inc., just 2 years old, is ready to move its lead product, Lixivaptan, into Phase III trials, and it raised $50 million to do so. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription